Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Gasbjerg, Lærke Smidt ; Gabe, Maria Buur Nordskov ; Hartmann, Bolette ; Christensen, Mikkel Bring ; Knop, Filip Krag ; Holst, Jens Juul ; Rosenkilde, Mette Marie. / Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. I: Peptides. 2018 ; Bind 100. s. 173-181.

Bibtex

@article{84d4e0c0170b4892b3c323ca58eba437,
title = "Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents",
abstract = "Glucose-dependent insulinotropic polypeptide (GIP) is an intestinal hormone with a broad range of physiological actions. In the postprandial state, the hormone stimulates insulin secretion and during eu- and hypoglycemia, it stimulates glucagon secretion. In addition, GIP increases triacylglycerol (TAG) uptake in adipose tissue and decreases bone resorption. However, the importance of these actions in humans are not clearly understood as a specific GIP receptor (GIPR) antagonist - an essential tool to study GIP physiology - has been missing. Several different GIPR antagonists have been identified comprising both peptides, vaccines against GIP, GIP antibodies or antibodies against the GIPR. However, most of these have only been tested in rodents. In vitro, N- and C-terminally truncated GIP variants are potent and efficacious GIPR antagonists. Recently, GIP(3-30)NH2, a naturally occurring peptide, was shown to block the GIPR in humans and decrease GIP-induced insulin secretion as well as adipose tissue blood flow and TAG uptake. So far, there are no studies with a GIPR antagonist in patients with type 2 diabetes (T2D), but because the elevations in fasting plasma glucagon and paradoxical postprandial glucagon excursions, seen in patients with T2D, are aggravated by GIP, a GIPR antagonist could partly alleviate this and possibly improve the fasting and postprandial glycemia. Since the majority of patients with T2D are overweight, inhibition of GIP-induced fat deposition may be beneficial as well. Here we summarize the studies of GIPR antagonists and discuss the therapeutic potential of the GIP system in humans.",
keywords = "Journal Article",
author = "Gasbjerg, {L{\ae}rke Smidt} and Gabe, {Maria Buur Nordskov} and Bolette Hartmann and Christensen, {Mikkel Bring} and Knop, {Filip Krag} and Holst, {Jens Juul} and Rosenkilde, {Mette Marie}",
note = "Copyright {\circledC} 2017 Elsevier Inc. All rights reserved.",
year = "2018",
month = "2",
doi = "10.1016/j.peptides.2017.11.021",
language = "English",
volume = "100",
pages = "173--181",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc",

}

RIS

TY - JOUR

T1 - Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents

AU - Gasbjerg, Lærke Smidt

AU - Gabe, Maria Buur Nordskov

AU - Hartmann, Bolette

AU - Christensen, Mikkel Bring

AU - Knop, Filip Krag

AU - Holst, Jens Juul

AU - Rosenkilde, Mette Marie

N1 - Copyright © 2017 Elsevier Inc. All rights reserved.

PY - 2018/2

Y1 - 2018/2

N2 - Glucose-dependent insulinotropic polypeptide (GIP) is an intestinal hormone with a broad range of physiological actions. In the postprandial state, the hormone stimulates insulin secretion and during eu- and hypoglycemia, it stimulates glucagon secretion. In addition, GIP increases triacylglycerol (TAG) uptake in adipose tissue and decreases bone resorption. However, the importance of these actions in humans are not clearly understood as a specific GIP receptor (GIPR) antagonist - an essential tool to study GIP physiology - has been missing. Several different GIPR antagonists have been identified comprising both peptides, vaccines against GIP, GIP antibodies or antibodies against the GIPR. However, most of these have only been tested in rodents. In vitro, N- and C-terminally truncated GIP variants are potent and efficacious GIPR antagonists. Recently, GIP(3-30)NH2, a naturally occurring peptide, was shown to block the GIPR in humans and decrease GIP-induced insulin secretion as well as adipose tissue blood flow and TAG uptake. So far, there are no studies with a GIPR antagonist in patients with type 2 diabetes (T2D), but because the elevations in fasting plasma glucagon and paradoxical postprandial glucagon excursions, seen in patients with T2D, are aggravated by GIP, a GIPR antagonist could partly alleviate this and possibly improve the fasting and postprandial glycemia. Since the majority of patients with T2D are overweight, inhibition of GIP-induced fat deposition may be beneficial as well. Here we summarize the studies of GIPR antagonists and discuss the therapeutic potential of the GIP system in humans.

AB - Glucose-dependent insulinotropic polypeptide (GIP) is an intestinal hormone with a broad range of physiological actions. In the postprandial state, the hormone stimulates insulin secretion and during eu- and hypoglycemia, it stimulates glucagon secretion. In addition, GIP increases triacylglycerol (TAG) uptake in adipose tissue and decreases bone resorption. However, the importance of these actions in humans are not clearly understood as a specific GIP receptor (GIPR) antagonist - an essential tool to study GIP physiology - has been missing. Several different GIPR antagonists have been identified comprising both peptides, vaccines against GIP, GIP antibodies or antibodies against the GIPR. However, most of these have only been tested in rodents. In vitro, N- and C-terminally truncated GIP variants are potent and efficacious GIPR antagonists. Recently, GIP(3-30)NH2, a naturally occurring peptide, was shown to block the GIPR in humans and decrease GIP-induced insulin secretion as well as adipose tissue blood flow and TAG uptake. So far, there are no studies with a GIPR antagonist in patients with type 2 diabetes (T2D), but because the elevations in fasting plasma glucagon and paradoxical postprandial glucagon excursions, seen in patients with T2D, are aggravated by GIP, a GIPR antagonist could partly alleviate this and possibly improve the fasting and postprandial glycemia. Since the majority of patients with T2D are overweight, inhibition of GIP-induced fat deposition may be beneficial as well. Here we summarize the studies of GIPR antagonists and discuss the therapeutic potential of the GIP system in humans.

KW - Journal Article

U2 - 10.1016/j.peptides.2017.11.021

DO - 10.1016/j.peptides.2017.11.021

M3 - Journal article

VL - 100

SP - 173

EP - 181

JO - Peptides

JF - Peptides

SN - 0196-9781

ER -

ID: 52667497